The use of iridaceae extract, the composition comprising it and method of cosmetic treatment

 

(57) Abstract:

The use of an extract of cells of at least one plant of the family Iridaceae in pharmaceutical compositions as an antagonist of CGRP and/or substance P. a Cosmetic or pharmaceutical composition containing an extract of cells of at least one plant of the family Iridaceae and the product with irritating or connection, reducing the synthesis or activity of a mediator of inflammation. Method of cosmetic treatment involving the use of one of the songs. The invention allows to obtain and apply standardized material for therapeutic and cosmetic treatment of skin, hair and mucous membranes. 7 C. and 46 C.p. f-crystals.

The invention relates to compositions containing an extract of cells of at least one plant of the family Iridaceae, to the use of these extracts as antagonists of CGRP (protein associated with the gene calcitonin) and/or substance P and to a method of cosmetic treatment, comprising one of the aforementioned compositions.

It is known that extracts of cells of at least one plant of the family Iridaceae described in the prior art, but their properties differ from the properties, izinski resources of the French flora) (1961, Vigot Freres, pp. 277-285)] describes the extract of saffron as a means of reinforcing menstruation, and also has antispasmodic effect.

In the patent application JP-A-07173148 described extracts Iridaceae containing genistein, a compound with estrogenic, anti-bacterial, antioxidant and/or anti-tumor activity.

In the application for Japanese Patent JP-A-62289509 describes cosmetic compositions intended to facilitate styling products that contain at least one Iridaceae extract.

In the application for Japanese Patent JP-A-62289509 describes cosmetic compositions for topical application which contain Iridaceae extract, which is designed to care for problem skin.

The applicant has demonstrated, after long research, the specific properties of the Iridaceae extract (as an antagonist of substance P, CGRP antagonist) and suggested the use of at least one extract of cells at one of the plants of the family Iridaceae as an antagonist of substance P and/or antagonist CGRP in cosmetic compositions or pharmaceutical compositions.

In the description below, the term "cells Iridaceae" should the duty to regulate to understand how the extract of the cells Iridaceae and, therefore, as the extract of cells of at least one plant of the family Iridaceae".

Extract of cells of at least one plant of the family Iridaceae, can be an extract prepared from any plant material derived from the family Iridaceae, with the specified material was obtained from cultures grown in vitro.

Breeding environment created by certain physico-chemical conditions that support during the growth of plant cells in vitro makes it possible to obtain a standardized plant material suitable for subsequent work throughout the year, unlike plants, cultivated in vitro.

In the context of the present description, the method of obtaining a culture in vitro covers the whole range of techniques known to any specialist, with an intermediate level of knowledge in this area, which provide an artificial image of the plant or part thereof.

Thus, in accordance with the present invention the specified extract may represent, for example, an extract of a body, or even cells of the body, at least one representative Iridaceae obtained in vitro culture (this can be to the necks least one representative Iridaceae.

Preferably use the extract derived from undifferentiated cells derived in turn from culture in vitro.

In the context of the present description, the term "undifferentiated cells of a plant" means any plant cell, not shown certain specific characteristics and which is able to live by itself, regardless of other cells. These undifferentiated plant cells can show the ability, under the influence of the inducing factor, differentiation, corresponding to the possibilities inherent in their genome.

In accordance with the selected method of cultivation and in particular depending on the culture medium can be obtained from the same Explant undifferentiated plant cells, having different characteristics.

The family Iridaceae (or Irid) includes about 750 species.

Plants of the family Iridaceae used mainly in connection with their fragrance or decorative properties.

Among the representatives of the genera of the family Iridaceae, which can be used according to the present invention, it is possible to specify, as an example, Romulea, Crocus (saffron), GLA use, you can mark the material obtained from Iris germanica, Iris florentina, and Iris pallida, Crocus versicolor, Romulea bulbucodium or Gladiolus communis.

More specifically, in accordance with the present invention using plant material obtained from Iris and, more specifically, from Iris pallida.

In the present invention can be used with any method of extraction known to every expert, with an intermediate level of knowledge in this field.

In particular, we can note an alcohol, in particular ethanol, extracts and aqueous-alcoholic extracts.

Can also be used with the extract obtained by the method described in the application for a French patent number 95-02379.

In accordance with the specified application in the first stage, the plant material is placed in an aqueous solution at low temperature, and in the second stage, the suspended particles are removed from the aqueous solution obtained in the first stage, and then at the third stage of sterile aqueous solution obtained in the second stage. This aqueous solution corresponds considered in this description of the extract.

In addition, the first stage can be successfully replaced by a simple operation of the freezing plant tccu stage, above.

Ways to make extracts, which can be used according to the present invention, as described later in examples.

The object of the present invention is also a cosmetic or pharmaceutical composition comprising as an active ingredient in a cosmetically or pharmaceutically acceptable medium, at least one extract of plant material of at least one representative Iridaceae defined above.

In the context of the present description, the term "active ingredient" refers to any molecule or extract that has the power to modify or modulate the function of at least one of the given biological system.

In mammals there are polypeptides belonging to the family of tachykinins, which induce rapid reduction of smooth muscle fibers. Among the compounds of this family can be noted b-neurokinin and-neurokinin and substance P.

Substance P is a polypeptide chemical component (undecapeptide), produced and released by nerve endings. The location of the substance P is specific and is associated with neurons located in the fabric receive afferent impulses from neurons, bearing substance P; in particular these include the salivary glands, stomach, pancreas, intestine (in the latter case, the distribution of substance P is subject to regulation under the influence of Massarosa and Horbachevsky plexus), cardiovascular system, thyroid gland, skin, iris and ciliary body, the bladder and, of course, the Central and peripheral nervous system.

In connection with the distribution of substance P on the entire body excessive synthesis and/or release of substance P may be accompanied by various disorders.

Substance P is involved, in particular, in the process of transmission in the Central nervous system diseases (such as anxiety, psychosis, neuropathy, neurodegenerative disorders, including senile dementia of Alzheimer's disease, AIDS dementia, Parkinson's disease, down's syndrome, Korsakov's syndrome, multiple sclerosis, schizophrenia), respiratory diseases (such as pneumonia) and in diseases of an inflammatory nature (such as, for example, rheumatoid arthritis, allergic syndromes (such as, for example, asthma, allergic rhinitis, allergic pharyngitis, beautiful, is she), in skin diseases (such as psoriasis, diseases accompanied by itch, herpes, photodermatosis, atopic dermatitis, contact dermatitis, lichen, prurigo, pruritus, erythema, particularly solar erythema, insect bites), fibrosis and other conditions associated with a disruption in the process of maturation of collagen (such as, for example, scleroderma), cardiovascular diseases, disorders associated with vascular spasms (such as migraine, Raynaud's disease), immunological disorders, when disruption of the functioning of the urinary tract (such as, for example, incontinence, cystitis), rheumatic diseases, in the case of some dermatological diseases (such as eczema) and in a number of eye conditions such as conjunctivitis, uveitis, itching in the eye area, pain in the eye area, irritation).

The use of an antagonist of the substance P is a therapeutic alternative that is effective in the case of all the above conditions.

In the context of the present description, the term "antagonist of the substance P" means any compound capable to inhibit partially or even fully biological effect of substance P. In frequent is a mini-reaction (including some version of its attachment to the receptor for substance P), especially in one of the following tests:

- the substance is an antagonist should reduce the allocation of plasma through the vascular wall induced by capsaicin or antidromic nerve stimulation, or

- the substance is an antagonist should cause inhibition of contraction of smooth muscles, caused by introduction substances P.

To date, the antagonists of substance P has been used to treat the above diseases and disorders. Currently, in this context, you can specify the following documents: US-A-4472305, US-A-4839465, EP-A-101929, EP-A-333174, EP-A-336230, EP-A-394989, EP-A-443132, EP-A-498069, EP-A-515681, EP-A-517589, WO-A-92/22569, GB-A-2216529, EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313, EP-A-514273, EP-A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A-528495, EP-A-532456, EP-A-545478, EP-A-558156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, WO-A-93/06099, WO-A-93/09116, EP-A-522808 and WO-A-93/01165.

However, none of the above documents is not considered or not considered that the extract of at least one representative of the family Iridaceae may have antagonistic against substance P activity, defined above, and therefore can be used for the treatment of the above disorders.

Theristicus for the antagonist of the substance P and therefore can be used as an antagonist of substance P.

CGRP is a chemical component of polypeptide nature, produced and released a nervous finish.

Location CGRP-specific and is associated with sensory nerve fibers (C-fibers). So, different organs or tissues receive afferent impulses from neurons that carry CGRP; in particular these include the salivary glands, stomach, pancreas, intestine, cardiovascular system, thyroid gland and skin.

In connection with the distribution of CGRP on the entire body excessive synthesis and/or release of CGRP may be accompanied by various disorders,

These include, in particular, respiratory diseases, allergic diseases, skin diseases, such dermatological conditions such as eczema, prurigo, rosacea.

The use of the CGRP antagonist is an alternative method of treatment that is effective in case the above conditions.

Under the CGRP antagonist should be understood as any substance that can inhibit partially or even fully biological effect of CGRP.

In particular substance, considered as a CGRP antagonist, should induce the appropriate farmacologiche the tests:

+ substance antagonist should reduce vasodilatation induced by capsaicin and/or antidromic electrical stimulation (imposed on afferent nerve) and/or

+ substance antagonist should cause inhibition of release of CGRP sensitive nerve fibers and/or

+ substance-antagonist should cause inhibition of contraction of smooth muscles in the excretory vessels induced by CGRP.

One of the known antagonists of CGRP may be cited as an example of CGRP 8-37 (the amino acid sequence of from 8 to 37 N-terminal region CGRP) or antibodies to CGRP.

Up to the present time has not been studied or even expected, that the extract of at least one representative Iridaceae may have antagonistic activity against CGRP.

The applicant has found that an extract of at least one representative Iridaceae meets the necessary characteristics for the CGRP antagonist and therefore can be used as an antagonist of CGRP.

All are in the texts examples, it was noted there was a link diseases with excessive synthesis and/or release of substance P or excessive synthesis and/or release C composition, comprising as an active ingredient, which is in cosmetically or pharmaceutically acceptable medium, at least one extract of plant material of at least one representative Iridaceae, intended for the treatment of disorders of the Central nervous system, respiratory disorders, allergic disorders, inflammation, pain, disorders of the gastrointestinal tract, skin diseases, fibrosis, impaired maturation of collagen, cardiovascular disorders, disorders related to vascular spasm, immunological disorders and/or diseases of the urinary tract.

In the case of skin disorders known that some types of skin are more sensitive than others, however the symptoms of sensitive skin have so far been insufficiently characterized, and problems related to such kinds of skin, were in this regard, it is ill-defined: no one knew exactly what processes are involved in the sensitization of the skin. Some believed that sensitive skin is skin that reacts to cosmetic products, others thought that this is a skin that reacts to various external factors, not obkak synonymous with allergic skin.

Was developed a number of tests sensitive skin, such as tests with the use of lactic acid and DMSO, which are known to be irritant substances: see, for example article Lammintausta et al. (K. Lammintausta et aL., Dermatoses, 1988, 36, p. 45-49) and article Agner and Serup (T. Agner and J. Serup, Clinical and Experimental Dermatology, 1989, 14, p. 214-217).

Due to lack of knowledge about the characteristics of sensitive skin until now been very difficult or even impossible to treat them. In fact, they were treated indirectly by limiting, for example, the use in cosmetic or dermatological compositions of the products with irritating properties, such as surfactants, preservatives, perfume, and use some cosmetically or dermatologically active agents.

After conducting numerous clinical trials the applicant was able to identify the symptoms associated with sensitive skin. These symptoms are mostly subjective signs and are mostly unpleasant sensations. Unpleasant sensations should be understood in the context of the present description as more or less painful sensations that occur at a particular site is the new sensation. Symptoms associated with this skin, can also be a microvascular signs of skin tissue, such as erythema.

The applicant could, in addition, show that sensitive skin is not allergic skin. In fact, allergic skin is a skin which reacts to an external agent, an allergen, which triggers an allergic reaction. This immunological process that occurs only in the presence of the allergen and which occurs only in individuals with high sensitivity. On the other hand, the fundamental characteristic of sensitive skin is in accordance with data obtained by the applicant, the mechanism of response to external factors that may affect any individual, although individuals with so-called sensitive skin reaction will occur faster than others. This mechanism is not immune and is nonspecific.

The applicant showed that in the group of sensitive skin can be separated into two main clinical forms, namely, irritated and/or reactive skin and intolerant skin.

Irritated and/or reactive skin on various environmental factors, emotional incentives to food stimuli, wind, rubbing, shaving, soap, surfactants, hard water containing high concentration of chalk, on the temperature and exposure to wool. Basically, these signs can occur if you have dry skin, with or without a pustular rash, as well as the skin showing signs of erythema.

Intolerant skin is a skin which reacts by the appearance of inflammatory sensations, shooting pains, formicaria and/or rash in response to various factors, such as environmental factors, emotional factors, food and some cosmetic products. Basically, these symptoms occur when hyperseborrhea skin or in the skin, with or without acne, in the presence or in the absence of pustular rash, as well as the presence of erythema.

Sensitive scalp characterized by a more universal clinical symptoms: sensation of itching and/or tingling and/or inflammation are run mainly by the impact factors of local character, such as a comb, soap, surfactants, hard water with a high concentration of chalk, shampoos or lotions. E and/or food. Often these symptoms are accompanied by the development of erythema and hyperseborrhea scalp and dandruff.

In addition, some anatomical sites such as the area that contains skin folds (groin, genital area, axillary region, popliteal region, the region of the anus, the region located under the breast or folds in the region of the elbow, and legs, sensitive skin reacts by cause itching and/or other unpleasant sensations (such as inflammation, tingling), primarily associated with sweating, the combing action of wool, surfactants, some cosmetic products, hard water containing high concentration of chalk, and/or temperature variations.

To determine whether this particular skin is sensitive or not the applicant has also developed the test. In fact, after conducting many tests in order to identify sensitive skin, it was found that there is a link between the response of persons with sensitive skin, and response, developing individuals after local application of capsaicin.

During capsaicinoid test put on at aktivnih signs, caused by such application, i.e. the emergence of tingling, burning and itching sensations. In individuals with sensitive skin these signs appear between 3 to 20 minutes after application and accompanied by the appearance of erythema that occurs initially on the peripheral area of application.

To date, capsaicin was used as a pharmaceutical drug used, in particular, to relieve pain, localized in certain areas. Capsaicin causes the release of neuropeptides, including CGRP and tachykinins, which originate from the nerve endings of the epidermis and dermis. The applicant has found that psychopathologische characteristics that are common to all States sensitive skin connected with high potential release of neuropeptides and tachykinins and, more specifically, CGRP and substance P in the skin. Unpleasant symptoms that can cause their release, defined by the term "neurogenic" state.

Nothing else to date, no link has been established between CGRP and sensitive skin and/or substance P and sensitive skin. Clinical manifestations sensitive skin are essentially subjective: this tingling, Formica. the tee signs are associated with nonspecific action of external factors. Emerging symptoms, usually limited only by the area of the face, neck and scalp, but can sometimes appear on the whole body.

Thus, the applicant has found that one of the principal characteristics of sensitive skin is associated with the release of CGRP and/or substance P, and therefore, the use of CGRP antagonists and/or an antagonist of substance P, including, in particular, the extract of plant material of at least one representative Iridaceae, may lead to a preventive and/or therapeutic effects on sensitive skin.

Thus, an object of the present invention is a cosmetic or pharmaceutical composition intended for sensitive skin, and which differs in that it includes a cosmetically or pharmaceutically acceptable medium, at least one extract of the plant material, as defined above, as an active ingredient.

For the treatment of sensitive skin, the applicant investigated the potential use of CGRP antagonists and/or antagonists of substance P. it Was shown that the inclusion of the CGRP antagonist and/or as is androgeny, and/or discomfort and/or itching of the skin and/or mucous membranes, and/or erythema and/or pustular rash, and/or inflammation.

In this regard, the subject of the present invention is a cosmetic or pharmaceutical composition intended for the treatment of skin irritation and/or discomfort and/or itching of the skin and/or mucous membranes, and/or erythema and/or pustular rash, and/or inflammation.

Mainly, according to the present invention, at least one extract of cells of at least one plant of the family Iridaceae can be successfully combined with products with irritating, which is usually used in cosmetic or pharmaceutical preparations and which are sometimes cosmetically or pharmaceutically active agents. The presence of the antagonist substance in the form of at least one extract of cells of at least one plant of the family Iridaceae in cosmetic or pharmaceutical compositions comprising the product, which has an irritating, can significantly reduce, or even remove this irritant effect.

In addition, it allows you to to increase the imago amount of the active ingredient for the purpose of enhancing the effectiveness of the composition. More specifically, the invention relates to cosmetic or pharmaceutical composition, characterized in that it includes a cosmetically or pharmaceutically acceptable medium at least one product with irritating, with the exception of ascorbic acid, and at least one extract of at least one representative Iridaceae.

The quality of the product with the irritant effects can result, for example, surfactants (ionic or nonionic), preservatives, organic solvents or active agents such as a-hydroxy acids (citric, malic, glycolic, tartaric, almond or lactic acid), a-hydroxy acids (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids (retinol, retinal, retinoic acid), anthralin (dioxiranes), anthranoid, peroxides (in particular, benzoylperoxide), Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, dyes or hair dye (paraphenylenediamine and its derivatives, aminophenols), perfume alcohol solution (perfume, toilet water, aftershave, deodorants, antiperspirants (some aluminium salts), active means for holding dailyaltace antagonist of the substance P allows in particular, the increase in 2-10 times the amount of the active ingredient, irritant effect, relative to currently used without the sense of the above-mentioned discomfort. So, hydroxy acids can be used in an amount up to 50 wt. % of the composition, and retinoids to 5 wt.% while significantly reducing their irritating.

Preferably the extract of at least one Iridaceae is an extract of the above description.

In addition, it is known that at the level of the skin takes place many of the phenomena of intolerance, the symptoms of which can be, in particular, subjective symptoms, and which basically represent the discomfort. In the context of the present description unpleasant sensations should be understood as more or less painful sensations that occur on a localized area of skin, such as tingling, formicaria, itching, itching, burning, inflammation, discomfort, shooting pain, etc.

These phenomena may be due to different phenomena, the cause of which is often irritation or inflammation, but some of them can be associated with physiological reasons, such as chuvstviteliyh also respond to the development of the inflammatory phenomena, shooting pains, formicaria and/or rash in response to the impact of various factors such as environmental factors, emotional factors, or food. In General, these signs are confined to hyperseborrhea skin or skin prone to acne, in the presence or absence of a pustular rash. In this case, these symptoms are also often accompanied by the appearance of erythema.

These phenomena can spread throughout the body, but most often they have a very precise localization, such as the scalp, face, skin folds and other

The range of phenomena intolerance is always determined by the presence of traditional inflammatory process and, more specifically, neurogenic inflammatory reaction type, since it involves the process of nerve fibers of the skin.

Allergic skin is a skin which reacts to an external agent, an allergen, which triggers an allergic reaction. For this reason, specified the process is specific immunological process that occurs only in the presence of the allergen and only in sensitized persons on the other hand, the end product of allergic reaction also contributes on the wow phenomenon features common to all mechanisms feature which leads to the development of inflammatory reactions, and end-stage which can be measured by the release of fat cells in the skin of at least one mediator of inflammation, such as histamine, serotonin, heparin, leukotrienes, prostaglandins, cytokines, nitrous oxide, or compounds containing reactive oxygen.

In some situations, such as, for example, in the case of sensitive skin, the whole mechanism is also under the control of sensitive nerve endings that release neuropeptides, including substance P and CGRP.

The present invention is to obtain the greatest effect in the treatment of all skin conditions and therefore provides a composition, which affects several components, typical for this kind of conditions.

Thus, in accordance with another aspect of the present invention relates to cosmetic or pharmaceutical composition containing a cosmetically or pharmaceutically acceptable medium extract of at least one representative Iridaceae and connection, reducing the synthesis, release and/or activity of at least one mediator of inflammation, except what stratcom, above in the present description.

Among steroid anti-inflammatory agents can be mentioned as an example hydrocortisone, betamethasone valerate or clobetasol propionate.

In the context of the present description non-steroidal anti-inflammatory drugs belong to the anti-inflammatory remedies specified Orderitem and Dyer [Schorderet and Dayer in Pharmacologie Des concepts fondamentaux aux applications therapeutiques (the Basic concept of therapeutic use), 1992, Chapter 37, pages 541-561, 2-nd edition, Frison-Roche/Slatkine editors)]. They all represent arylcarbamoyl acids such as salicylic acid derivatives or derivatives of Anthranilic acid, arylalkenes acid, such as akriluksusnoy and heteroepitaxy acid or arylpropionate acid, enol acids such as derivatives of pyrazolone or oxycam, non-acidic derivatives, such as, for example, bufexamac (Merck Index, 11th edition (M. I.) 1462), benzydamine (M. I. 1136), epirizole (M. I. 3572), flurocarbon (M. I. 4120) or tiaramide (M. I. 9356).

Preferably the composition according to the present invention includes a compound that reduces the synthesis, release and/or activity of at least one mediator of cutaneous inflammation in combination with the extract, the floor and/or activity of at least one mediator of inflammation, cook, preferably choosing from antagonists of substance P and/or CGRP, inhibitors synthase nitrous oxide, antagonists of bradykinin antagonists of cytokines, histamine antagonists, antagonists compounds of the type of tumor necrosis factor (TNFa).

Preferably use receptor antagonists.

In accordance with the present invention can, for example, to use one or more antagonists of substance P, is selected from peptides, ones compounds, such as, for example, include at least one nitrogen-containing heterocycle compounds comprising at least one benzene ring, salts of monovalent, divalent and trivalent cations, thermal waters and their mixtures.

As a peptide antagonist of the substance P may be used according to the present invention Sanded and Spantide II.

Sended has the following formula: Tyr-D-Phe-Phe-D-His Leu Met NH2in which

Tyr represents a tyrosine,

D-Phe denotes a D-phenylalanine,

Phe represents phenylalanine,

D-His means of D-histidine,

Leu represents leucine,

Met indicates methionine.

Spantide II has the following formula:

D-NicLys Pro 3-Pal Pro D-Cl2Phe Asn D-Trp Phe D-Trp Leu Nle NH2 is DIL-alanine,

D-Cl2Phe denotes a D-dichlorophenylamino,

Asn denotes asparagine,

D-Trp represents D-tryptophan,

Phe represents phenylalanine,

Leu represents leucine,

NLe denotes norleucine.

In addition, as a peptide, which has antagonistic activity against substance P, can be used peptides described in the following documents: US A-4472305, US-A-4839465, EP-A-101929, EP-A-333174, EP-A-336230, EP-A-394989, EP-A-443132, EP-A-498069, EP-A-515681, EP-A-517589, WO-A-92/22569 and GB-A-2216529.

Ones antagonists of substance P, which can be used according to the present invention, include, in particular, to the compounds containing heteroatom connected directly or indirectly to the benzene ring, or which may be contained in the heterocycle. In particular such heteroatom is an atom of oxygen, nitrogen or sulfur.

As heterocyclic compounds in the present invention can be used, in particular, those that were described in the following documents: EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313, EP-A-514273, EP-A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A-528495, EP-A-532456, EP-A-545478, EP-A-558156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, heterocycl, is a derivative of 2-tricyclic-2-aminoethane, derived spirolactone, derived hinoklidina, azollaceae derived, derived aminopyrrolidine, piperidino derived, aminoheterocycles or isoindoline derived.

As other heterocyclic compounds can be called oxygen-containing or sulfur-containing heterocyclic compounds such as furan derivatives, benzopyrane derivatives, thiophene derivatives, benzothiophene derivatives, which are optional nitrogen-containing substituents, such as, for example, heterocyclic compounds described in documents US-A-4931459, US-A-4910317, EP-A-229457 and, more specifically, alkoxy - and/or aryloxy-tetrazolyl-benzofuran-carboxamide and alkoxy - and/or aryloxy-tetrazolyl-benzothiophen-carboxamide.

As compounds containing a nitrogen atom linked directly or indirectly to the benzene ring are those of them which are listed in the following documents: EP-A-522808 and WO-A-93/01165 and WO-A-93/10073.

Salts and cations that can be used in the present invention include, in particular, salts of strontium, magnesium, lanthanides of atomic number from 57 to 71, the particular, to represent carbonates, salicylates, bicarbonates, sulphates, glycerophosphate, borates, chlorides, nitrates, acetates, hydroxides, persulfates, as well as salt-gidromolot (including salts of citric, tartaric, lactic, malic acid) or of fruit acids, or it may be salts of amino acids (aspartate, arginate, glycocholate, fumarate) or salts of fatty acids (palmitate, oleate, Caseinate, beginat). Preferably, the specified salt selected from strontium nitrate, manganese, yttrium or magnesium, strontium borate, manganese, yttrium or magnesium, strontium chloride, manganese or magnesium and magnesium sulfate, manganese or strontium. Even more preferably, these salts are chloride or strontium nitrate.

Among thermal waters, which can be used according to the present invention, it may be noted, in particular, thermal water Vichy, such as water obtained from sources Celestine (Celestins), Somali (Chomel), Grand Barbecue, Grande-Grille), Hospital (Hopital, Lucas and Parc (Park). Preferably, in accordance with the present invention, use water from a source Lucas.

Antagonists of substance P may be used singly or as a mixture.

In the context of the present invention antagonist CGSS="ptx2">

In particular substance, considered as a CGRP antagonist, should induce the appropriate pharmacological response (including or, on the contrary, his attachment to the CGRP receptor), in particular in one of the following tests:

+ substance antagonist should reduce vasodilatation induced by capsaicin and/or antidromic electrical stimulation (imposed on afferent nerve) and/or

+ substance antagonist should cause inhibition of release of CGRP sensitive nerve fibers and/or

+ substance antagonist should cause inhibition of contraction of smooth muscles in the excretory vessels induced by CGRP.

One of the known antagonists of CGRP may be cited as an example of CGRP 8-37 (the amino acid sequence of from 8 to 37 N-thermal plot CGRP) or antibodies to CGRP.

Antagonists of CGRP may be used singly or as a mixture.

The term NO-synthase, synthase or nitrous oxide, covers virtually all family of enzymes that are capable of specific way to carry out the catalytic conversion of L-arginine, citrulline, which is produced by a gaseous mediator that performs multiple functions, and it is th makes it highly reactive. Currently, it is well known that such compounds are very harmful, and in this regard, been various attempts to limit their formation in the body. Therefore, in the case of nitrous oxide inhibitors of NO-synthase were sufficiently well understood.

Thus, in accordance with this invention, the inhibitors of NO-synthase are products that allow in situ in the human body, to inhibit partially or even completely the synthesis of nitrous oxide (NO).

In this regard, they are compounds which are selected from compounds inhibiting the synthesis and/or accelerating the disintegration of NO-synthase, compounds, neutralizing NO-synthase, or compounds involved in the reduction of the signal transmitted NO-synthase.

Thus, the inhibitor of NO-synthase selected from synthetic or natural peptides, which can be optionally modified, synthetic or natural chemical molecules, antisense nucleic acids, ribozymes, and antibodies to the NO-synthase.

Among these inhibitors of NO-synthase, in particular, to be called the NG-monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine methylated ester of NG-nitro-L-arginine, PI is UP>G-dimethylarginine, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyldisilazane-1-oxy-3-oxide, aminoguanidine, canavanine, ebselen and melanocyte-stimulating hormone type .

Among the inhibitors of NO-synthase is preferred to use NG-monomethyl-L-arginine and melanocyte-stimulating

hormone type . Inhibitors of NO-synthase can be used singly or as a mixture.

Bradykinin is a peptide plasma origin, which is released from predecessor kininogen using plasma protease called kallicrein (EU 3.4.21.24). This nonapeptide refers to the number of key mediators of inflammation and has mitogenic properties. Receptors such cenina can be divided into two different subtypes: B1 and B2. Bradykin acts specifically on the B2 receptor and causes stimulation of the different systems and the formation of second messengers, including the hydrolysis of insiteful, arachidonic acid metabolism, phosphorylation of tyrosine residues, as well as depolarization hyperpolarized cell membrane.

Activation of some receptors causes activation of phospholipase C and therefore leads to the formation of Inositol 1,4,5-trifast what about the pool in the cells, including keratinocytes. Calcium, which acts as activator and regulator of numerous enzymes (proteases, phospholipases), plays an important role in the regulation of differentiation and proliferation of keratinocytes.

In the context of the present description, the antagonist of bradykinin refers to any compound capable to inhibit partially or even fully biological effect of bradykinin.

In particular, the substance is considered as the antagonist of bradykinin, should induce the appropriate pharmacological response that includes some version of its attachment to the receptor of bradykinin.

Thus, in accordance with the definition of such an inhibitor is any compound that interferes with the action of bradykinin by attaching to the receptor of bradykinin (B1 or B2) and/or any connection that, regardless of the implementation process of attaching to the receptor(s), induced by any mechanism, the inverse effect of bradykinin (for example, preventing the synthesis of bradykinin).

Among the antagonists of bradykinin is preferred to use those compounds which inhibit the synthesis and/or accelerate the decay repeatsthe action of bradykinin by binding to the receptor last (B1 or B2), compounds that inhibit the synthesis of bradykinin receptor, or compounds that play a role in the attenuation of the signal transmitted by bradykinin. Such compounds can be both natural and synthetic.

Among the antagonists of bradykinin can be called synthetic or natural peptides, which can be optionally modified, such as, for example, D-Arg, [Hep3, D-Phe7]-bradykinin (NPC567), [Thi 5,8, D-Phe7] - bradykinin, D-Arg, [Hyp3, Thi 5,8,D-Phe7]-bradykinin, N-a-adamantaneacetic-D-Arg, [Hyp3, Thi5,8,0-Phe7]-bradykinin, des-Arg9, [Leu8]-bradykinin (all offered by the company Sigma) or connections specified in the patents WO 95/08566, WO 95/07294, EP 0623350, EP 0622361, WO 94/11021, EP 0596406, WO 94/06453, WO 94/09001, EP 0578521, EP 0564972, EP 0552106, WO 93/11789, US 5216165, US 5212182, WO 92/17201, EP 0496369, EP 0472220, EP 0455133, WO 91/09055, WO 91/02746, EP 0413277, EP 0370453, EP 0359310, WO 90/03980, WO 89/09231, WO 89/09230, WO 89/01780, EP 0334244, EP 0596406, WO 86/07263 or P-gandavensis, [Hep3, Thi5, D-Tic7, Oci8]-bradykinin (S 16118) (Feletou M. et al. , Pharmacol. Exp. Ther., June 1995, 273, 1078-84), D-Arg, [Hep3, Thi5, D-Tic7, Oic8]-bradykinin (HOE 140) (Feletou M. et al., Eur. J. Pharmacol. , 1995, 274, 57-64), D-Arg, [Hep3, D-Hype (TRANS-propyl)7 Oci8]-bradykinin (NPC 17731) (Herzig M. C. S. and Leeb-Lundberg L. M. F., J. Biol. Chem., 1995, 270, 20591-20598) or those that were mentioned in the works is their organic or chemical molecules, such, in particular, which were described in Salvino et al. (Salvino et. al., J. Med. Chem., 1993, 36, 2583-2584).

You can also in the framework of the present invention to use antisense nucleic acids, or ribozymes, the function of which consists in the inhibition of the synthesis of bradykinin. Such antisense nucleic acids are known to every expert with the average level of knowledge in this area. They can in various ways to affect DNA or messenger RNA encoding bradykinin, in particular by blocking the attachment or broaching of ribosomes along the messenger RNA, by cleavage of the RNA by RNA-Asai H or by creating obstacles to the transport of mRNAs from the nucleus to the cytoplasm or, in the alternative, obstacles to the process of maturation of the RNA.

It is also possible in accordance with the present invention to use antibodies to bradykinin or soluble receptors for bradykinin, antibodies to the receptor of bradykinin or antagonists of the bradykinin receptor.

Preferably, according to the method of the present invention is used as a compound that prevents the manifestation of the effects of bradykinin by procrea the use of the present invention antagonist of bradykinin, which to choose from:

D-Arg, [Hep3, D-Phe7]-bradykinin (NPC567),

[Thi 5,8,D-Phe7]-bradykinin,

D-Arg, [Hep3, Thi5,8D-Phe7]-bradykinin,

N - adamantaneacetic-D-Arg,

[Hep3, Thi5,8,D-Phe7]-bradykinin,

des-Arg9, [Leu8]-bradykinin,

P-gandavensis, [Hyp3, Thi5, D-Tic7, Oci8] -bradykinin (S 16118),

D-Arg, [Hyp3, Thi5,D-Tic7, Oci8]-bradykinin (HOE 140),

D-Arg, [Hyp3, D-Hype (TRANS-propyl)7 Oci8]-bradykinin (NPC 17731).

From the number of modified peptides in the present invention is used preferably D-Arg, [Hyp3,Thi5,D-Tic7,Oci8]-bradykinin (NOAH 140).

Antagonists of bradykinin can be used singly or as a mixture.

It is also known that substance P released sensitive endings of the epidermis, induces a series of biochemical reactions, and the first stage in this series is localized in mastocyte. The attachment of the substance P receptor of mastocytes induces the release of a number of proinflammatory mediators, including histamine cytokines, such as interleukin-1 [IL-1 (IL-1)], interleukin-6 [IL-6 (IL-6) and interleukin-8 [IL-8 (IL-8)] and the connection type of the tumor necrosis factor (TNF ).

In the context of the present invention, the antagonists of histamine, cytokines and/or TNF indicate substances that can inhibit the release, and ingibiruyushee attaching to the receptor of histamine, are funds that are specific for histamine receptor type I (H1).

Substance, considered as a receptor antagonist of histamine, cytokines, or TNF, ; must meet the following characteristics:

it must have affinity to receptors specific for these compounds;

- it must have antagonistic pharmacological activity against histamine receptors, cytokines and TNF, i.e., it must induce the appropriate pharmacological response in one of the following tests:

+ for receptor histamine antagonist: inhibition of smooth muscle contraction induced by the introduction of histamine;

+ for receptor antagonists tsitokinov: to inhibit the adhesion of macrophages to endothelial cells induced by cytokines, or to inhibit the release of superoxide anions, which cytokine to induce neutrophils;

+ for the receptor of the TNF antagonists: inhibition of adhesion of macrophages to endothelial cells induced by TNF, or to inhibit the release of superoxide anions, which induces TNF on neutrophils, or to inhibit the mitogenic activity of TNF on the fibroblasts of the dermis.

Substance, new:

it must inhibit the release of histamine by mastocytoma stimulated by compound 48/80 or stimulated calcium ionophores (A23 187),

it must inhibit the release of cytokines or TNF by monocytes (U937 cells), during the differentiation under the influence forblog ester (PMA).

The receptor antagonists of the histamine H1, which can be used in the present invention include those that traditionally were used for treatment of allergic and anaphylactic conditions, as well as to treat diseases of travelers. Such compounds can, for example, be derived of diethylenediamine, such as Cinnarizine or cyclizine; derivatives aminopropane, such as dexchlorpheniramine, triprolidine; the phenothiazines, such as promethazine, alimemazine and connections, see pages 116-118 book Prosa (Joseph R. Prous, The Year's Drug News, Therapeutic Targets, 1994 edition, Prous Science Publishers), such as cetirizine-HCl, Bastin, loratadine, settin-HCl.

Inhibitors of the release of histamine, first of all, oxygen-containing or sulfur-containing heterocyclic compounds such as furan derivatives, benzopyrane derivatives, timescale, such, in particular, those described in documents US-A-4931459, US-A-4910317 and EP-A-299457 and, more specifically, it relates to alkoxy - and/or aryloxy-tetrazol-Il-benzofuran-carboxamide or alkoxy and/or aryloxy-tetrazol-Il-benzothiophen-carboxamide. As an example, can be called 5-methoxy-3-phenoxy-M-1H-tetrazol-5-yl-benzothiophene - 2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl - benzothiophene-2-carboxamide, 6-methoxy-3-(1-methylethoxy)-N-1H - tetrazol-5-yl-benzothiophene-2-carboxamide, 5-methoxy-3-(1 - methylethyl)-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 3-benzyloxy-5-methoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide and 5-methoxy-3-phenoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide.

Among the antagonists of cytokines, which can be used according to the present invention, it should be noted, for example, the antagonist release of interleukin-1, which can represent auranofin or SKF-105809 or, alternatively, the antagonist of the synthesis of interleukin-1, which can be a lactoferrin.

The receptor antagonists and inhibitors of TNF release and/or synthesis of TNF, which can find application for the present invention include, in particular, lipophilin, A, sulfasalazin.

Antagonists of histamine, cytokines, and TNF can be used according to the present invention, either individually or in combination by themselves or in a mixture.

The number of compounds contained in the compositions of the present compound, which can reduce the synthesis, release and/or activity of at least one mediator of inflammation, depends, no doubt, from the effect that it is desirable to obtain, and can be varied within wide limits.

To obtain a significant effect of the cosmetic composition of the present invention may contain a compound that reduces the synthesis, release and/or activity of at least one mediator of inflammation, in number, comprising from 0.001% to 5% by weight of the composition, and preferably in a quantity of 0.01% to 2% by weight of the total composition.

To obtain a significant effect of pharmacological composition of the present invention may contain a compound that reduces the synthesis, release and/or activity of at least one mediator of inflammation in number, comprising from 0.001% to 10% by weight of the composition, and preferably in a quantity of 0.01% to 5% of the total composition.

Nisha least one Iridaceae depends undoubtedly, on the desired effect and may be varied within wide limits.

To obtain a significant effect, if we consider the composition is a cosmetic composition, it may contain an extract of at least one Iridaceae in number, comprising from 0.001% to 20% by weight of the total composition and preferably in amounts of 0.1% to 10% by weight of the total composition.

To obtain a significant effect, if we consider the composition is a pharmaceutical composition, it may contain an extract of at least one Iridaceae in the amount of 0.1% to 30% by weight of the total composition and preferably in amounts of 0.5% to 20% by weight of the total composition.

The composition according to the present invention can be administered orally, parenterally or applied on the skin (on any area of skin on the body), the hair, the nails or the mucous membranes (buccal, zygomatic, gingival, genital, conjunctival). Depending on the method of introduction of the composition according to the present invention can be prepared in different commonly used herbal forms of drugs.

The composition for topical application to the skin may, in particular, be the th consistency of the milk type, which is obtained by dispersing a fatty phase in an aqueous phase (W/W) or conversely (W/W), or of suspensions or emulsions of soft consistency of the type of aqueous or anhydrous cream or gel, or, alternatively, microcapsules or microparticles, or of vesicular dispersions of ionic and/or nonionic type. Such compositions can be obtained using conventional methods.

They can also be used for application to the hair in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions, foams or, in the alternative, in the form of compositions suitable for use in aerosol form, which include a pressurized propellant.

Composition for injection can be prepared in the form of aqueous or oily lotion or serum. For applying the composition in the eye it can be prepared in the form of drops, and for oral administration in the form of capsules, granules, syrup or tablets.

The number of different components of the compositions of the present invention corresponds traditionally used in this field.

Such compositions are, in particular, in the form of creams for cleansing, protection, obro can be for example, day creams, night creams, creams for removing makeup, creams, sunscreen milk), liquid tones of creams, milk to remove make-up, jelly for body and for preventive care body sunscreen milk, lotions for skin care, gels or foams, such as cleansing lotions, sun lotions, lotions, tanning in the form of products for the bath, deodorant compositions containing a bactericidal agent, gels or lotions after shaving, creams for hair removal, compositions against insect bites, analgesic compositions compositions for treating certain skin diseases such as eczema, rosacea, psoriasis, herpes, severe itching.

The compositions of the present invention can also be a solid preparations, including cleansing briquettes or soap.

The composition can also be designed for use in aerosol cans, and include in this case a compressed propellant.

The composition according to the present invention can also provide a composition for hair care, in particular, it may be the shampoo, lotion, hair lotion for hair care, gel or cream for UKL what una, lotions to restore weakened hair, a composition for permanent waving of hair (in particular compositions for the first stage of the permanent waving), lotion or gel against hair loss, antiparasitic shampoo, etc.

The composition can also be prepared for transbukkalno applications, for example in the form of toothpaste. In this case, the composition may include conventional adjuvants and additives used in products intended for intraoral use and, in particular, surfactants, thickeners, humectants, polishing agents such as silica, various active ingredients such as fluorides, in particular sodium fluoride, and optionally sweeteners such as sodium saccharinate.

In that case, when the composition is an emulsion, the proportion of the fatty phase can range from 5 wt.% up to 80 wt.% and preferably from 5 wt. % to 50 wt. % by weight of the entire composition. Oils, waxes, emulsifiers and auxiliary emulsifiers used in the composition according to the type of emulsion, choose from traditionally used in cosmetology.

Emulsifier and auxiliary emulsifier are present in the composition in amounts varying the but include lipid vesicles.

In that case, when the composition is an oily gel or solution, the proportion of the fatty phase may represent more than 90 wt.% by weight of the entire composition.

Known manufacturing techniques cosmetic compositions, in accordance with which the latter can contain the usual cosmetic use of adjuvants, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes and fragrances, fillers, sunscreen agents, odor absorbers and coloring agents. Number of different adjuvants are similar to those traditionally used in cosmetics and make up, for example, from 0.01 wt.% up to 10 wt.% by weight of the entire composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and/or into the lipid with ferule.

As an example, oils or waxes which can be used according to the present invention, can result in mineral oil (petrolatum), vegetable oils (liquid fraction of Shea butter, sunflower oil), animal fats (perhydrosqualene), synthetic oils (porcelanowe oil), silicone oils or waxes (cyclomethicone) and fluorine is also fatty alcohols and fatty acids (stearic acid).

As examples of emulsifiers which can be used in the present invention include literallayout, Polysorbate 60 and the PEG-6/PEG-32/Glycol stearate mixture, sold under the trademark Tepos63 (Tefose63) the company Gattefosse (Gattefosse).

As examples of solvents used in the present invention, can be called the lower alcohols, in particular ethanol and isopropanol, and propylene glycol.

As an example of geleobrazovanie can be called carboxyvinyl polymers (carbomer), acrylic polymers such as copolymers of acrylate and alkylacrylate, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents may be mentioned modified clays such as Bentone, metal salts on the basis of fatty acids such as aluminum stearates, and hydrophobic silica, ethylcellulose, polyethylene.

The composition can also contain other hydrophilic agents, such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and derivatives of sugars, water-soluble vitamins, plant extracts and hydroxine spodnie, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives.

The composition of the present invention may include at least one extract of at least one representative of Iridaceae with other active funds meant for the prevention and/or treatment of certain skin conditions. Among these active agents can be mentioned as an example the following:

- means, modulating skin pigmentation and/or proliferation and/or differentiation, such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, oestrogens such as oestradiol, kojic acid or hydroquinone;

- antibacterial agents such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline;

- antiparasitic means, in particular metronidazole, crotamiton or pyrethrinoid;

- antifungal agents, in particular compounds belonging to the class of imidazoles, such as econazole, ketoconazole or miconazole or their salts, polyene compounds such as amphotericin b, compounds of the family of allylamines, such as terbinafine or, in the alternative varenye means, such as hydrocortisone, betamethasone valerate, clobetasol propionate, or nonsteroidal anti-inflammatory drugs such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;

- anestesiologia tools such as lidocaine hydrochloride and its derivatives;

- antipruritic agents such as analgin, trimeprazine or cycloheptadiene;

- keratolytic agents such as alpha - and beta - hydroxycarbonate or beta-ketocarboxylic acids, their salts, amides or esters and more specific - hydroxyacids such as glycolic acid, lactic acid, salicylic acid, citric acid and, in General, fruit acids, and n-octane-5-salicylic acid;

means against free radicals, such as alpha-tocopherol and its esters, superoxide dismutase, some chelating agents with metals or ascorbic acid and its esters;

- antiseborrheic tools such as progesterone;

- anti-dandruff, such as octopirox or zinc pyrithione;

- anti-acne, such as retinoic acid and benzoyl peroxide.

Thus, in accordance with A at least one extract of at least one representative Iridaceae and at least one agent, selected from an antibacterial, antiparasitic, antifungal, antiviral, anti-inflammatory, antipruritic, analiziruemykh, keratolytic funds, funds directed against free radicals, antiseborrheic equipment, dandruff, acne, and/or means, modulating skin pigmentation and/or proliferation and/or differentiation.

In addition, an object of the present invention is also a method of cosmetic treatment, reducing the irritant effect of a cosmetic, non-therapeutic composition, which consists in applying to the skin, hair and/or mucous membranes above cosmetic compositions.

Method of cosmetic treatment according to the present invention can be implemented, for example, by applying customary for such compositions by the method of hygienic or cosmetic compositions. For example: by applying creams, gels, serums, lotions, milk to remove make-up or sunscreen compositions to the skin or dry hair, by applying lotion to the hair on wet hair, and applying shampoos or, alternatively, applying toothpaste to the gums.

The following examples are the common components listed in mass%.

Example 1. Preparation of extract of Iris pallida.

Undifferentiated cells of Iris pallida, obtained by cultivation in vitro under sterile conditions, separated from the culture in Erlenmeyer flask or fermenter, by filtration through a sieve size 50 mm To 55 mg of freshly prepared thus material added 27.5 ml of demineralised water. The mixture is precipitated [Potter, Ultra Turax (Potter, Ultra Turax) and others] in the device Turks with the speed of 24000 rpm./min for 1 min at 4oC (ice bath). The precipitated product is centrifuged with a speed of 10000 g for 15 minutes at 4oC. the Supernatant is filtered through a filter with pore size 0.22 mm (sterilized by filtration).

Thus prepared, the extract is stored at a temperature of 4oC It contains about 15 g of dry material per liter.

If the plant material is a whole plant, fresh intended for further processing of the material carried out the determination of dry weight, in order to comply with the same in vitro conditions of extraction. Select different parts of the plant in accordance with the relative weight of each plant part. Cold treatment translates into geleobraznye available in the environment by microorganisms. Finally, the filler in the form of water, which is compatible with the receptors ex vivo facilitates the preparation of cosmetic or pharmaceutical compositions.

Example 2. Measurement of the affinity of the receptor of the extract of undifferentiated cells Iris pallida (Example 1) with respect to the human NK1 receptor (the receptor for substance P in humans).

A) the Affinity of the receptor:

Measurement of the affinity of the receptor of the extract of undifferentiated cells Iris pallida about the human NK1 receptor carried out according to the method described in the article Hoyle et al. (Heuillet, E. et al., J. Neurochem. 60, 1993, 868-876).

The extract was examined at concentrations of 1%, 5% and 10%.

During each experiment the molecule a model for the studied receptor ([Sar9, Met (O2)11]-SP, analogue of substance P, as described in Hoyle et al. (Heuillet, E. et al., J. Neurochem. 60, 1993, 868-876)) are examined in 8 parallel concentrations (n = 2)to obtain a standard curve, which would allow to assess the acceptability of this experiment.

The following results were obtained:

26.8 per cent level of binding of the extract from Example 1 at a concentration of 1%,

43.5% of the level of binding of the extract from Example 1 at a concentration of 5%,

89.3 per cent level of binding of innosti extract from undifferentiated cells of the Iris pallida in respect of the human receptor for substance P, starting with a concentration of 1%.

Curve affinity, constructed in accordance with the obtained results indicate a 50% substitution of natural ligand (IR50) extract of Iris pallida at a concentration of 2%.

B) a Functional test in vitro:

Functional test in vitro is carried out with the use of human NK1 receptor present on smooth muscle highlighted intestines (powszechna intestine), to demonstrate antagonistic towards substance P character of the extract from undifferentiated cells of the Iris pallida.

In vitro experiments carried out by the method described in the work of Dion et al. (Dion et al., Life Sciences, 41, 1987, 2269-2278), Patacchini et al. (Patacchini et al., Eur. J. Pharmacol, 215, 1992, 93-98).

After the introduction in the experimental tanks tissue (smooth muscle) are exposed to the source voltage in 1 year during the period balance, of at least 60 minutes, during which saline is replaced several times, and the source voltage is applied to the desired level, conduct surveillance prior to the introduction of the extract.

Experiments carried out at constant presence of atropine (3 of 10-6M) and indomethacin (10-6M) u is Perov, available in this fabric.

Each drug is initially stimulated by the agonist substance P: [Sar9, Met (O2)11] -SP at a concentration of 10-8M order to obtain reference values contractility, and then saline fully updates.

This operation is repeated every 40 minutes in the presence of increasing concentrations of the extract of Iris pallida, with each such extract add 30 minutes to make [Sar9, Met (O2)11]-SP.

When using the extract at a concentration of 7% receive 50% inhibition activity [Sar9, Met (O2)11]-SP.

In Functional in vivo test:

Functional in vivo test carried out on the model of neurogenic inflammation to demonstrate antagonistic in relation to substance P, the nature of the extract of Iris pallida (Example 1).

The in vivo experiments carried out by the method described in the literature (Chi, X. L. et al., Neurosciences, 1991, 42, 731-737).

Within this text antidromic stimulation of the saphenous nerve on Vienna legs shot animals cause inflammation. The specified nerve innervates the skin of the hind limbs.

Stimulation causes the release of the population determine quantitatively measuring the permeability of fabrics to dye Evans blue (Evans blue), which is a marker of tissue extravasation of plasma albumin, which occur when the inflammation.

To test in vivo antagonists of substance P using the standard model. Extract of Iris pallida in aqueous form, diluted in a ratio of 1/10, causes a statistically significant decrease in 38% of neurogenic inflammation.

Conclusion:

Extract of undifferentiated cells Iris pallida has affinity to the receptor, substance P and manifests specific antagonistic activity against substance P.

Example 3. Measurement of affinity to the receptor in the extract of undifferentiated cells Iris pallida (Example 1) in respect of the CGRP receptor.

A) the Affinity of the receptor:

Determination of affinity to the receptor, peculiar to extract the undifferentiated cells of the Iris pallida from Example 1 in respect of the CGRP receptor, performed according to the method described Mima et al. (Mimeault, M. et al., J. Med. Chem. 35, 1992, 2163-2168).

The extract was examined at concentrations of 0.5%, 1% and 5%.

During each experiment the molecule a model for the studied receptor (creation hCGRPa, similar to CGRP, described Mima et al. (Mimeault, M. EA would allow to assess the acceptability of this experiment.

The following results were obtained:

17% - the level of binding of the extract from Example 1 at a concentration of 0.5%;

36% - the level of binding of the extract from Example 1 at a concentration of 1%;

100% - the level of binding of the extract from Example 1 at a concentration of 5%.

The results of the above experiment demonstrates the affinity of the extract from undifferentiated cells of the Iris pallida in relation to human CGRP receptor, starting with a concentration of 0.5%.

Curve affinity, constructed in accordance with the obtained results indicate a 50% substitution of natural ligand (IR50) extract of Iris pallida at a concentration of 2.5%.

B) a Functional test in vitro:

Functional test in vitro is carried out with the use of CGRP receptors present on smooth muscle of the VAS deferens, to demonstrate antagonistic towards CGRP nature of the extract of Iris pallida.

The ex vivo experiments carried out by the method described in Longmore et al. (Longmore et al., Eur. J. Pharmacol. 265, 1994, 53-59).

After the introduction in the experimental tanks tissue (smooth muscle) is exposed to the source voltage in 1 year during the period balance, sostavlyayuscyeye is brought to the desired level, supervise.

After this period conduct electrical stimulation of the smooth muscle of the VAS deferens, the extract added after stabilization of the contractile response induced by the imposed stimulus, which is about 30 minutes.

Experiments carried out at constant presence of thiorphan (10-5M) for inhibiting the decomposition of CGRP and its analogues available in fabric endopeptidase.

Each drug is exposed to hCGRPa (analog CGRP) at a concentration of 10-8M order to obtain inhibitory control values.

After stabilization of the specified reaction increases the concentration of extract of Iris pallida or hCGRP and test cumulative recovery of contractility due to the action of such compounds, which indicates that their antagonism against CGRP receptors.

Extract of Iris pallida also examine three other concentrations of the constituents of 0.5%, 1% and 5% of its initial concentration.

The results obtained are comparable to those characteristic of the reference molecules. The number of drugs used in each case, equal to 2 (n=2).

After a previous inhibition of contractions induced hCGRp, EXT is shown hCGRPa.

When using the extract at a concentration of 0.8% achieved 50% inhibition of activity hCGRPa.

Conclusion:

Extract of undifferentiated cells Iris pallida has affinity to the receptor for CGRP and shows specific antagonistic activity against CGRP.

Example 4. Examples of the preparation of compositions illustrating the present invention. The present compositions have a simple mixing of the various components.

Composition 1. Lotion to remove makeup from the face.

The extract of Example - 5,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 2. Gel for skin care of the face.

The extract of Example 1 - 0,50

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 3. Care cream for the face (oil-water emulsion)

The extract of Example 1 is 2.00

Glyceraldehyd - 2,00

Polysorbate 60 (tween 60sold by Isii (ICI)) - 1,00

Stearic acid - 1,40

Triethanolamine - 0,70

Ka is RNA odorant - 0,50

Preservative - 0,30

Q water.s. Up to 100%

Composition 4. Shampoo

The extract of Example 1 - 0,50

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Perfume perfume - 0,5

Preservative - 0,30

Q water.s. Up to 100%

Composition 5. Gel to relieve pain

The extract of Example 1 - 5,00

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Antioxidant - 0,05

Lidocaine hydrochloride - 2,00

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 6. Anti-wrinkle cream for the care of the skin (emulsion oil/water)

The extract of Example 1 - 0,15

Stearate glycerin - 2,00

Polysorbate 60 (tween 60sold by Isii (ICI) - 1,00

Stearic acid - 1,40

n-Octanoyl-5-salicylic acid - 0,50

Triethanolamine - 0,70

Carbomer - 0,40

The liquid fraction of Shea butter - 12,00

Perhydrosqualene - 12,00

Antioxidant - 0,05

Perfume perfume - 0,5

Preservative - 0,30

Q water.s. Up to 100%

Composition 7. Cream against solar erythema (oil-water emulsion)

Extract P is th (ICI)) - 1,40

Stearic acid - 1,40

Glycyrrhetinic acid - 2,00

Triethanolamine - 0,70

Carbomer - 0,40

The liquid fraction of Shea butter - 12,00

Sunflower oil - 10,00

Antioxidant - 0,05

Perfume perfume - 0,50

Preservative - 0,30

Q water.s - 100%

Composition 8. Gel for treatment of acne

The extract of Example 1 - 5,00

All-TRANS-retinova acid - 0,05

Hydroxypropylcellulose (Klucel H) - 1,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 9. Lotion for removing scars from acne

The extract of Example 1 - 5,00

Glycolic acid - 50,00

Hydroxypropylcellulose (Klucel H) - 0,05

NaOH q.s - Up to a pH of 2.8

Ethanol q.s. Up to 100%

Preservative - 0,30

Composition 10. Lotion to remove makeup from the face

The extract of Example 1 - 5,00

Strontium chloride 5,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 11. Gel for skin care facial

The extract of Example 1 - 5,00

Thermal water Vichy - 10,00

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Antioxi the face (oil-water emulsion)

The extract of Example 1 - 5,00

Auranofin - 0,10

Stearate glycerin - 2,00

Polysorbate 60 (tween 60sold by Isii (ICI)) - 1,00

Stearic acid - 1,40

Triethanolamine - 0,70

Carbomer - 0,40

The liquid fraction of Shea butter - 12,00

Perhydrosqualene - 12,00

Antioxidant - 0,05

Preservative - - 0,30

Q water.s. Up to 100%

Composition 13 Shampoo

The extract of Example 1 - 5,00

Strontium chloride 5,00

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Perfume perfume - 0,50

Preservative - 0,30

Q water.s. Up to 100%

Composition 14. Lotion for removing scars from acne

The extract of Example 1 - 5,00

HOE 140 - 0,05

Glycolic acid - 50,00

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 0,05

NaOH q.s. Up to a pH of 2.8

Ethanol q.s. Up to 100%

Preservative - 0,30

Composition 15 face Cream against solar erythema (oil-water emulsion)

The extract of Example 1 - 5,00

Thermal water Vichy - 10,00

Stearate glycerin - 2,00

Polysorbate 60 (tween 60sold by Isii (ICI)) - 1,00

Steari the fraction of Shea butter - 12,00

Sunflower oil - 10,00

Antioxidant - 0,05

Perfume perfume - 0,50

Preservative - 0,30

Q water.s - 100%

Composition 16. Gel for treatment of acne

The extract of Example 1 - 5,00

CGRP 8-35 - 0,50

All-TRANS-retinoic acid - 0,05

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Q water.s - 100%

Composition 17. Composition for relieving pain

The extract of Example 1 - 5,00

Spantide II - 0,05

Hydroxypropylcellulose [Klucel H(Klucel H) sold by the company Hercules (Hercules)] - 1,00

Antioxidant - 0,05

Lidocaine hydrochloride - 2,00

Isopropanol - 40,00

Preservative - 0,30

Q water.s. Up to 100%

Composition 18. Anti-wrinkle cream for the care of the skin (emulsion oil/water)

The extract of Example 1 - 5,00

Lactoferrin - 1,00

Stearate glycerin - 2,00

Polysorbate 60 (tween 60sold by Isii (ICI)) - 1,00

Stearic acid - 1,40

n-Octanoyl-5-salicylic acid - 0,50

Triethanolamine - 0,70

Carbomer - 0,40

The liquid fraction of Shea butter - 12,00
the and q.s. Up to 100%

1. The use of at least one extract of cells of at least one plant of the family Iridaceae in a cosmetic composition or for the preparation of pharmaceutical compositions as an antagonist of CGRP and/or substance P.

2. The use of at least one extract of cells of at least one plant of the family Iridaceae in a cosmetic composition or for the preparation of pharmaceutical compositions as an antagonist of CGRP or for treating disorders associated with excessive synthesis and/or release of CGRP and/or substance P, except for respiratory disorders.

3. The use of at least one extract of cells of at least one plant of the family Iridaceae in a cosmetic composition or for the preparation of pharmaceutical compositions for the treatment of disorders of the Central nervous system, allergic syndromes, inflammation, pains, disorders of the gastrointestinal tract, fibrosis, disorders in the process of maturation of collagen, cardiovascular disorders, disorders caused by vascular spasm, immunological disorders and/or disorders of the urinary tract.

4. Applying at least one extene pharmaceutical composition for preventing and/or combating eritem, and/or itching of the skin and/or mucous membranes.

5. The use according to any one of paragraphs.1 to 4, characterized in that said extract is prepared from cells derived from a genus of the family Iridaceae, selected from Romulea, Crocus (saffron), Iris (iris), Gladiolus (gladiolus), and Sisyrinchium Hermodactylus.

6. Application under item 5, characterized in that said extract is prepared from cells derived from the genus Iris family Iridaceae.

7. Application under item 6, characterized in that said extract is prepared from cells derived from Iris pallida.

8. The use according to any one of paragraphs.1 to 7, characterized in that said extract is prepared from cells of plant material derived from in vitro culture.

9. The use according to any one of paragraphs.1 to 8, characterized in that said extract is prepared from undifferentiated cells.

10. Cosmetic or pharmaceutical composition that does not contain ascorbic acid, characterized in that it contains in a cosmetically or pharmaceutically acceptable medium extract of cells of at least one plant of the family Iridaceae and at least one product with the irritant.

11. The composition according to p. 10, characterized in that the product with irritating choose from IO is tov, such as a-hydroxy acid, a-hydroxy acid, keto acid, a keto acid, retinoids, anthralin, anthranoid, peroxides, Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, dyes or hair dye, perfume and alcohol solutions, antiperspirant active agents for carrying out waxing, active preparations for permanent waving of hair, depigmenting active funds.

12. Cosmetic or pharmaceutical composition that does not contain koiwai acid, characterized in that it contains in a cosmetically or pharmaceutically acceptable medium extract of cells of at least one plant of the family Iridaceae and connection, reducing the synthesis, release, and/or activity of at least one mediator of inflammation.

13. The composition according to p. 12, characterized in that the specified connection, reducing the synthesis, release, and/or activity of at least one mediator of inflammation is a compound that reduces the synthesis, release and/or activity of at least one mediator of inflammation of the skin.

14. Composition under item 12 or 13, characterized in that the specified connection, reducing the synthesis, release, and/or activity is entasy, antagonists of bradykinin antagonists of cytokines, histamine antagonists, antagonists of tumor necrosis factor tissue type (THF).

15. The composition according to p. 14, characterized in that the said antagonist is an antagonist attach to the receptors.

16. Composition according to any one of p. 14 or 15, characterized in that the antagonist of the substance P is selected from substances which impair the allocation of plasma through the vascular wall induced by capsaicin or antidromic nerve stimulation, and substances that cause inhibition of contraction of smooth muscles, caused by introduction substances, R.

17. Composition according to any one of paragraphs.14 to 16, characterized in that the antagonist of substance P are selected from peptides, compounds comprising at least one heterocycle, nitrogen-containing compounds comprising at least one benzene ring, salts of monovalent, divalent and trivalent cations, thermal waters and their mixtures.

18. The composition according to p. 17, characterized in that this peptide represents Tyr-D-Phe-Phe-D-His-Leu-Met-NH2where Tyr is tyrosine, D-Phe-D-phenylalanine, Phe is phenylalanine, D-His-D-histidine, Leu is leucine, Met-methionine or D-Nic Lys-Pro-3-Pal Pro D-dichlorophenylamino, Asn-asparagine, D-Trp-D-tryptophan, Phe is phenylalanine, Leu is leucine, Nle-norleucine.

19. The composition according to p. 17, characterized in that the said connection comprising at least one heterocycle is a nitrogen-, oxygen - or structurae heterocyclic compound selected from derivatives of 2-tricyclic-2-aminoethane, derived spirolactone, derivatives of hinoklidina, usacycling derivatives, derivatives of aminopyrrolidine, derivatives of piperidine, aminoheterocycles, isoindoline derivatives, furan derivatives, benzofuran derivatives, thiophene derivatives, benzothiophene derivatives and in particular tetrazolyl-benzofuran-carboxamido or tetrazolyl-benzothiophen-carboxamido.

20. The composition according to p. 17, wherein the specified salt selected from chlorides, acetates, carbonates, bicarbonates, salicylates, borates, nitrates, hydroxides, sulfates, persulfates, glycerophosphates, salts of hydroxy acids, salts of fruit acids, salts of amino acids and salts of fatty acids strontium, magnesium, lanthanides of atomic number from 57 to 71, cobalt, Nickel, manganese, barium, yttrium, copper, tin, rubidium, lithium and zinc.

21. The composition according to p. 20, characterized t is I, that said salt is a chloride or nitrate of strontium.

23. The composition according to p. 17, characterized in that thermal water is water obtained from a source in the pool Vichy.

24. The composition according to p. 23, wherein the specified thermal water is obtained from sources Celestine (Celestins), Somali (Chomel, Grande Grill (Grande-Grille), Hospital (Hopital, Lucas and Parc (Park).

25. Composition according to any one of p. 23 or 24, characterized in that the specified thermal water is obtained from a source Lucas (Lucas).

26. Composition according to any one of p. 14 or 15, characterized in that the CGRP antagonist is selected from substances that lead to reduced vasodilation induced by capsaicin and/or inhibition of release of CGRP sensitive nerve fibers.

27. The composition according to p. 26, wherein the CGRP antagonist selected from CGRP 8 - 37, where the numbers indicate the sequence of the amino acids on the N/a terminal area CGRP or of antibodies to CGRP.

28. The composition according to p. 14, characterized in that the inhibitor of NO-synthase is selected from substances which allow in situ in the human body to achieve partial or even complete inhibition of the synthesis of nitrous oxide (NO).

Li accelerating the disintegration of NO-synthase, compounds, neutralizing NO-synthase or compounds that play a role in the reduction of the signal transmitted NO-synthase.

30. Composition according to any one of paragraphs.28 and 29, characterized in that the inhibitor of NO-synthase selected from optionally modified synthetic or natural peptides, synthetic or natural chemical molecules, antisense nucleic acids, ribozymes, and antibodies to the NO-synthase.

31. Composition according to any one of paragraphs.28 to 30, characterized in that the inhibitor of NO-synthase selected from NG-monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine methylated ether N-nitro-L-arginine, chloride diphenylbenzidine, 7 nitroindazole, N-(5)-(1-iminoethyl)-L-ornithine, NGNG-dimethyl-L-arginine, NGNGdimethylarginine, [2-(4-carboxyphenyl)-4,4,5,5-tetramethyldisilazane-1-oxy-3-oxide, ebselen, aminoguanidine, canavanine and methanolic-stimulating hormone type .

32. Composition according to any one of paragraphs.28 to 31, characterized in that the inhibitor of NO-synthase is the NG-monomethyl-L-arginine and melanocyte-stimulating hormone type .

33. Composition according to any one of p. 14 or 15, characterized in that the antagonist of bradykinin are selected from compounds that inhibit sintezator bradykinin, such, for example, which prevent the action of bradykinin by binding to the receptor last (B1 or B2), compounds inhibiting the synthesis of bradykinin receptor or compounds that play a role in the attenuation of the signal transmitted by bradykinin.

34. The composition according to p. 33, wherein the antagonist of bradykinin choose from optional modified synthetic or natural peptides, synthetic or natural chemical molecules, antisense nucleic acids, ribozymes, antibodies to bradykinin or antagonists of the bradykinin receptor.

35. Composition according to any one of paragraphs.33 and 34, wherein the antagonist of bradykinin are selected from compounds that inhibit the action of bradykinin by binding to the receptor last B1 or B2 and preferably with the B2 receptor.

36. Composition according to any one of paragraphs.33 to 35, characterized in that the antagonist of bradykinin choose from D-Arg-[Hyp 3, D-Phe 7]-bradykinin (NPC 567), [Thi 5,8, D-Phe 7]-bradykinin, D-Arg, [Hyp 3, Thi 5,8, D-Phe 7]-bradykinin, N--adamantaneacetic-D-Arg-[Hyp 3, Thi 5,8, D-Phe 7]-bradykinin, des-Arg 9, { Leu 8] -bradykinin, P-gandavensis-[Hyp 3, Thi 5, D-7 Tic, Oic 8]-bradykinin(S16118), D-Arg-[Hyp 3, Thi 5, D-7 Tic, Oic 8]-bradykinin(HOE 140), D-Arg-[Hyp 3, D-Hype(TRANS-propyl)7 O the ina is a D-Arg-[Hyp 3, Thi 5, D-7 Tic, Oic 8]-bradykinin (HOE 140).

38. Composition according to any one of p. 14 or 15, characterized in that the antagonist of histamine, cytokines or TNF is a substance selected from the receptor antagonists of histamine, cytokines or TNF or antagonists release and/or synthesis of histamine, cytokines or TNF.

39. The composition according to p. 38, wherein the substance is selected from receptor antagonists of histamine, cytokines or TNF is a substance having a selective affinity to specific receptors of these compounds, or leading to inhibition of contraction of smooth muscles induced by the injection of histamine, or leading to the inhibition of adhesion of macrophages, which was induced by cytokines on endothelial cells, or inhibition of release of superoxide anions, which was induced by cytokines, naafilah, or to inhibition of adhesion of macrophages, which was induced by TNF on endothelial cells, or inhibition of release of superoxide anions, which was induced by TNF on neutrophils or inhibition of the mitogenic activity of TNF on the fibroblasts of the dermis.

40. Composition according to any one of p. 38 Il is Cinnarizine or cyclizine; derivative aminopropane, such as dexchlorpheniramine, triprolidine; the phenothiazines, such as promethazine, alimemazine, cetirizine HCl, Bastin, loratadine, settin HCl.

41. The composition according to p. 38, wherein the antagonist release of histamine selected from oxygen or serosoderjaschei heterocyclic compounds such as furan derivatives, benzopyrane derivatives, thiophene derivatives and benzothiophene derivatives, not necessarily incorporating the nitrogen-containing substituents, preferably alkoxy - and/or kilometersa-yl, benzofuran-carboxamido or alkoxy and/or kilometersa-Il-benzothiophen-carboxamido.

42. Composition according to any one of paragraphs.38 to 41, characterized in that the antagonist release of histamine choose from 5-methoxy-3-phenoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 6-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 5-methoxy-3-(1-methylethyl)-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 3, -benzyloxy-5-methoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide and 5-methoxy-3-phenoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide.

44. The composition according to p. 38, wherein the receptor antagonist and inhibitors of TNF release and/or synthesis of TNF choose from lisofylline, A, sulfasalazin.

45. Composition according to any one of paragraphs.10 - 44, characterized in that the compound that reduces the synthesis, release and/or activity of at least one mediator of inflammation, is used in amounts of 0.001 - 5% by weight of the entire composition, and preferably in an amount of 0.01 - 2% by weight of the entire composition.

46. The pharmaceutical composition according to any one of paragraphs.10 - 44, characterized in that the compound that reduces the synthesis, release and/or activity of at least one mediator of inflammation, is used in amounts of 0.001 - 10% by weight of the entire composition, and preferably in an amount of 0.01 - 5% by weight of the entire composition.

47. Composition according to any one of paragraphs.10 - 46, intended for the treatment of disorders of the Central nervous system, respiratory disorders, allergic syndromes, inflammation, pains, disorders of the gastrointestinal tract, skin disorders, fibrosis, impaired maturation of collagen, cardiovascular R is o paths.

48. Composition according to any one of paragraphs.10 - 47 intended for preventing and/or combating skin irritations and/or pustular rash, and/or eritem, and/or discomfort, and/or inflammatory conditions, and/or itching of the skin and/or mucous membranes.

49. Composition according to any one of paragraphs.10 - 48, characterized in that it includes a cosmetically or pharmaceutically acceptable medium at least one product with the irritant.

50. Composition according to any one of paragraphs.10 - 49, characterized in that the extract of at least one plant of the family Iridaceae corresponds to the definitions given in paragraphs.1 to 9.

51. Cosmetic composition according to any one of paragraphs.10 - 45 or 47 to 50, characterized in that the extract is used in a quantity of 0.001 - 20% by weight of the composition and preferably in an amount of 0.1 - 10% by weight of the entire composition.

52. The pharmaceutical composition according to any one of paragraphs.10 - 44 or 46 to 50, characterized in that the Iridaceae extract is used in an amount of 0.1 - 30% by weight of the entire composition, and preferably in quantities of 0.5 - 20% by weight of the entire composition.

53. The way non-therapeutic cosmetic treatment, characterized in that the cosmetics / products in an effective amount.

Priority points:

07.09.95 on PP.1 - 12, 53;

27.03.96 on PP.13 - 45;

07.09.95 on PP.46 - 52, when they depend on PP.10 and 11;

27.03.96 on PP.46 - 52, when they depend on PP.12 - 50.

 

Same patents:
The invention relates to medicine applies balm-ointment for the treatment of deep and extensive burns and infected wounds and ulcers

The invention relates to chemical-pharmaceutical industry, refers to a stable solution palmitate, treatment of skin diseases and reducing the side effects of chemotherapy for cancer patients

- cyano)-,-diphenylethylamine, use,- diphenylacetamide or (-cyano)-,- diphenylacetate, the method of stabilization of the composition and method of cosmetic treatment of the skin and/or hair" target="_blank">

The invention relates to novel cosmetic and/or dermatological compositions comprising cosmetically and/or dermatologically acceptable medium, 4-tert.-butyl-4'-methoxybenzanilide at least one derivative of 1,3,5-triazine, at least,-diphenylacetamide or (-cyano)-,-diphenylethylamine, as well as to a method of stabilization and to a method of cosmetic treatment of the skin and/or hair

The invention relates to the development of safe and effective tools that increase the speed of delivery of physiologically active agents through the skin or mucous membrane of the mouth

The invention relates to medicine and the pharmaceutical industry and relates to a means of stimulating the reparative processes in tissues
The invention relates to medicine, namely to pharmaceutical compositions for removal of benign growths on the skin and mucous membranes (papillomas, warts, nevi, warts, cutaneous cysts, xantom, atheroma, angiomas, keloid scars, as well as cervical erosion), and methods of obtaining such funds

The invention relates to pharmaceutical industry and can be used in medical institutions and in the home as a remedy to stop bleeding during surgical interventions, as well as in industrial and domestic injuries
The invention relates to medicine and can be used to prepare therapeutic baths, body wraps, facial masks, etc
The invention relates to medicine and cosmetic industry and relates to curative and preventive cosmetic

The invention relates to the field of dentistry and the receipt of the product for teeth whitening and treatment of skin diseases of the mucous membranes

The invention relates to cosmetic and is a means to care for the skin, in particular lotion, cosmetic alcohol containing propolis extract thick, herbal Supplement "Erakond, ethyl alcohol and water

The invention relates to medicine, namely can be used for treatment and cosmetic skin care
The invention relates to medicine and can be used to prepare therapeutic baths, body wraps, facial masks
The invention relates to medicine, namely to dermatology

Mask for skin care // 2164131
The invention relates to cosmetics

The invention relates to the cosmetic industry and can be used in medicine for dermatitis, eczema, burns, psoriasis, acne, osteoarthritis, polyarthritis, rheumatism, bruises, scoliosis

The invention relates to cosmetic compositions for treatment of keratin fibers (hair), containing the carrier: (a) one enzyme type oxidoreductase, with 2 electrons in the presence of one donor for the enzyme; (b) one nonionic amphiphilic polymer containing one fatty chain and one hydrophilic element; and to methods of treatment of keratin fibres, and in particular to methods of dyeing, permanent treatment or bleaching the hair with the use of this composition and to a kit box for hair coloring
Up!